Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 4/20 | 0.73 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | HBB | P68871 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 5/20 | 0.66 |
| ▸ | GAPDH | P04406 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421820 | 1.00 | HSPA8 (0.73) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL6840072 | 1.00 | HSPA8 (0.73) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL2452214 | 0.96 | HSPA8 (0.68) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL30237271 | 0.90 | HSPA8 (0.60) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL6761939 | 0.90 | HSPA8 (0.72) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL6761931 | 0.90 | HSPA8 (0.72) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL17406892 | 0.88 | HSPA8 (0.56) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL18858928 | 0.86 | HSPA8 (0.80) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL15906323 | 0.86 | HSPA8 (0.80) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL1135195 | 0.86 | HSPA8 (0.80) | HSPA8HSPA5RXFP1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136756-A1 | COMBINATION ANTITUMOR THERAPY | BIOSSIL INC. (CA) | 2011-06-09 | — | — | US | claimed |
| EP-2296645-A2 | COMBINATION ANTITUMOR THERAPY | Kereos, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009143454-A2 | COMBINATION ANTITUMOR THERAPY | KEREOS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-1194168-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078941-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2000-12-28 | — | — | WO | claimed |
| EP-4746875-A2 | CARCINOGENESIS REDUCTION WITH PENTAAZA MACROCYCLIC RING COMPLEX | Galera Labs, LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | OHIO STATE INNOVATION FOUNDATION (US) | 2026-02-26 | — | — | US | disclosed |
| US-12551581-B2 | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | GALERA LABS, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2005070126-A2 | METHODS AND COMPOSITIONS FOR TREATING HUMAN DISEASES AND WOUNDS WITH UCP AND FAS INHIBITORS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050059617-A1 | Novel anitsense oligonucleotide derivatives against to hepatitis c virus | TAKESHI IMANISHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1437408-A1 | NOVEL ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST HEPATITIS C VIRUS | Imanishi, Takeshi (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20030150022-A1 | Compositions and methods for regulating metabolism in plants | UNIVERSITY OF COLORADO-COLORADO SPRINGS | 2003-08-07 | — | — | US | disclosed |
| WO-2001075131-A9 | EXPRESSION OF UNCOUPLING PROTEIN (UCP) IN PLANTS | UNIV TECHNOLOGY CORP (US) | 2002-12-27 | — | — | WO | disclosed |
| EP-1194168-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001075131-A2 | EXPRESSION OF UNCOUPLING PROTEIN (UCP) IN PLANTS | UNIVERSITY TECHNOLOGY CORPORATION (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000078941-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | ARG1, ARG2, PDE6D | HSPA8 2686/4885HSPA5 1771/4885RXFP1 733/4885 |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | CYP4X1, SLC6A7, ZFX | HSPA8 3937/4885HSPA5 2271/4885RXFP1 781/4885 |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | PHAX, RNMT, PRKCZ | HSPA8 2379/4885HSPA5 3202/4885RXFP1 1660/4885 |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | HSPA8 1863/4885HSPA5 3033/4885RXFP1 744/4885 |
| US-12551581-B2 | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | CD274, PDCD1, PDCD1LG2 | HSPA8 1931/4885HSPA5 3894/4885RXFP1 498/4885 |
| US-20110136756-A1 | COMBINATION ANTITUMOR THERAPY | SOD3, SOD1, MCL1 | HSPA8 557/4885HSPA5 1025/4885RXFP1 4331/4885 |
| US-20050059617-A1 | Novel anitsense oligonucleotide derivatives against to hepatitis c virus | RNGTT, NSUN2, RNASE1 | HSPA8 641/4885HSPA5 300/4885RXFP1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.